VISACards AcceptedFree Shipping Over $300GTA Third-Party TestedShips Canada-Wide3+ Vials — 10% Off5+ Vials — 20% Off10+ Vials — 40% OffVISACards AcceptedFree Shipping Over $300GTA Third-Party TestedShips Canada-Wide3+ Vials — 10% Off5+ Vials — 20% Off10+ Vials — 40% Off
Coming Soon

ARA 290

10 mg (lyophilized)

Purity:

≥99% (HPLC)

ARA 290 10 mg (lyophilized) research vial
Research peptide · RUO · Canada

ARA 290

10 mg (lyophilized)

Formula
N/ACAD · per vial

+ $25 flat-rate shipping · free at $300+ · Interac e-Transfer · VISA

1
Inquire
Purity≥99% (HPLC)
Storage-20°C
FormLyophilized
TestingHPLC
🏦Interac e-Transfer
COA policy·Returns

About this compound

ARA 290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the helix B surface of erythropoietin (EPO). Unlike full-length EPO, ARA 290 selectively binds to the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the beta common receptor (βcR) — without activating erythropoiesis. Preclinical and early clinical research has examined ARA 290 for its neuroprotective, anti-inflammatory, and tissue-repair properties in models of peripheral neuropathy, ischemia, and chronic inflammatory conditions. It has been studied in the context of small fiber neuropathy associated with sarcoidosis and type 2 diabetes.

Storage and handling

Lyophilized storage

Store at -20°C lyophilized, away from moisture and UV light. Keep vials sealed until use. Stable for 2+ years in a non-frost-free freezer.

Preclinical research references

Provided for informational context only. All cited studies involve preclinical or in vitro models. Results do not predict human safety or efficacy. These references do not constitute medical claims.

  • Rodent peripheral nerve injury models demonstrated that ARA 290 administration improved axonal regeneration and myelination, with statistically significant improvements in sensory nerve conduction velocity compared to vehicle controls (Brines et al., 2008)
  • Mouse models of ischemia-reperfusion injury showed ARA 290 reduced pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) and attenuated tissue damage in cardiac and renal injury paradigms through IRR-mediated signaling (Brines et al., 2012)
  • Phase 2 clinical investigation in sarcoidosis-associated small fiber neuropathy demonstrated improvements in intraepidermal nerve fiber density and patient-reported neuropathy symptom scores following ARA 290 administration (Culver et al., 2017)

Shipping & returns

Shipping

1–5 business days, Canada-wide tracked courier, double tamper-proof packaging.

Returns

All sales final. Damaged or incorrect orders must be reported within 24 hours with photos.

Quality assurance

Every batch independently tested for purity. COA on file and available before purchase.

FAQ — ARA 290

For research use only. Not for human or veterinary administration.

Research updates

Stay ahead of new batches.

New compounds, COA releases, batch testing results, and research content — straight to your inbox.

Research Use Only (RUO): All products are strictly for laboratory research. Not for human or veterinary use. Full disclaimer →